한지훈 (고려대학교, KIST) | 한빛사논문 > 한빛사

한빛사논문

조회547

고려대학교, KIST

Adv. Sci., Apr 26 2024, | https://doi.org/10.1002/advs.202308662 Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity

Jihoon Han^1,2, Seohyun Kim^1,2,3, Yeong Ha Hwang ^1,2, Seong A Kim ^1,2, Yeji Lee ^1,2, Jihong Kim ^1,2, Seongeon Cho^1,2, Jiwan Woo⁴, Cherlhyun Jeong ^2,5, Minsu Kwon ⁶, Gi-Hoon Nam^3,7, In-San Kim^1,2

¹KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul, 02841, Republic of Korea.

²Chemical and Biomedical Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.

³Department of Research and Development, ShiftBio, Seoul, 02751, Republic of Korea.

⁴Research Animal Resource Center, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.

⁵KHU-KIST Department of Converging Science and Technology, Kyung Hee University, Seoul, 02447, Republic of Korea.

⁶Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.

⁷Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, 02841, Republic of Korea.

J.H. and S.K. contributed equally to this work.

CORRESPONDING AUTHOR : In-San Kim

Abstract

Cancer vaccines offer a promising avenue in cancer immunotherapy by inducing systemic, tumor-specific immune responses. Tumor extracellular vesicles (TEVs) are nanoparticles naturally laden with tumor antigens, making them appealing for vaccine development. However, their inherent malignant properties from the original tumor cells limit their direct therapeutic use. This study introduces a novel approach to repurpose TEVs as potent personalized cancer vaccines. The study shows that inhibition of both YAP and autophagy not only diminishes the malignancy-associated traits of TEVs but also enhances their immunogenic attributes by enriching their load of tumor antigens and adjuvants. These revamped TEVs, termed attenuated yet immunogenically potentiated TEVs (AI-TEVs), showcase potential in inhibiting tumor growth, both as a preventive measure and a possible treatment for recurrent cancers. They prompt a tumor-specific and enduring immune memory. In addition, by showing that AI-TEVs can counteract cancer growth in a personalized vaccine approach, a potential strategy is presented for developing postoperative cancer immunotherapy that's enduring and tailored to individual patients.

논문정보

형식Research article
게재일2024년 04월 (BRIC 등록일 2024-04-30)
연구진국내 연구진
분야 바이오·의료융합 > 바이오센싱 및 나노바이오물질

댓글 작성 로그인

CV 열람하기

연락처 보기